Summit Therapeutics Shares Down 5.9 percent Should You Sell?
| SMMT Stock | USD 18.94 0.26 1.35% |
Slightly above 53% of Summit Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Summit Therapeutics PLC suggests that some traders are interested. Summit Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Summit Therapeutics' earnings reports, geopolitical events, and overall market trends.
Summit |
Shares of Summit Therapeutics Inc. fell 5.9 percent on Wednesday . The company traded as low as 18.80 and last traded at 18.83. 819,138 shares traded hands during trading, a decline of 77 percent from the average session volume of 3,553,185 shares. The stock had previously closed at 20.00. Wall Street Analysts
Read at thelincolnianonline.com
 |
Summit Therapeutics PLC Current Investor Sentiment
Panic Vs Confidence
53
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Summit Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Summit Therapeutics PLC.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentAcquiring |
Summit Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Summit Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Summit Therapeutics PLC Historical Investor Sentiment
Investor biases related to Summit Therapeutics' public news can be used to forecast risks associated with an investment in Summit. The trend in average sentiment can be used to explain how an investor holding Summit can time the market purely based on public headlines and social activities around Summit Therapeutics PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Summit Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Summit Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Summit Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Summit Therapeutics.
Summit Therapeutics Fundamental Analysis
We analyze Summit Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Summit Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Summit Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Summit Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Summit Therapeutics PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Summit Therapeutics stock to make a market-neutral strategy. Peer analysis of Summit Therapeutics could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics with similar companies.
Peers
Summit Therapeutics Related Equities
| NKTX | Nkarta | 14.56 | ||||
| KRON | Kronos Bio | 10.34 | ||||
| PHIO | Phio Pharmaceuticals | 5.18 | ||||
| CGEM | Cullinan Oncology | 2.51 | ||||
| ZURA | Zura Bio | 0.33 | ||||
| KZR | Kezar Life | 0.40 | ||||
| ATNF | 180 Life | 0.45 | ||||
| ELEV | Elevation Oncology | 1.59 | ||||
| OCEA | Ocean Biomedical | 2.74 | ||||
| CDIO | Cardio Diagnostics | 3.23 | ||||
| ZVSA | ZyVersa Therapeutics | 3.60 | ||||
| SONN | Sonnet Biotherapeutics | 5.05 |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.